anakinra

Phase 1/2Completed

1 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Mucopolysaccharidosis III

Conditions

Mucopolysaccharidosis III

Trial Timeline

Jan 30, 2020 → Mar 8, 2023

NCT ID

NCT04018755

About anakinra

anakinra is a phase 1/2 stage product being developed by Swedish Orphan Biovitrum for Mucopolysaccharidosis III. The current trial status is completed. This product is registered under clinical trial identifier NCT04018755. Target conditions include Mucopolysaccharidosis III.

What happened to similar drugs?

5 of 15 similar drugs in Mucopolysaccharidosis III were approved

Approved (5) Terminated (1) Active (10)

✅laronidaseSanofiApproved

✅LaronidaseSanofiApproved

✅Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiApproved

🔄Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 3

🔄rhIDU (recombinant human-Alpha-L-Iduronidase) + PlaceboSanofiPhase 3

🔄Aldurazyme + Aldurazyme + placeboSanofiPhase 3

✅LaronidaseSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06666335	Approved	Recruiting	Sep 1, 2025	Nov 30, 2027	Familial Mediterranean Fever (FMF )
NCT04359784	Phase 2	Completed	Dec 27, 2021	Dec 23, 2024	B-Cell Non-Hodgkin Lymphoma
NCT04018755	Phase 1/2	Completed	Jan 30, 2020	Mar 8, 2023	Mucopolysaccharidosis III
NCT03932344	Pre-clinical	Completed	Apr 10, 2019	Aug 31, 2019	Still Disease, Juvenile Onset
NCT02390596	Phase 2	Completed	Feb 5, 2016	Feb 18, 2019	Kawasaki Disease
NCT02915094	Pre-clinical	Completed	Oct 1, 2012	Jan 1, 2016	Rheumatoid Arthritis

Competing Products

20 competing products in Mucopolysaccharidosis III

See all competitors

Product	Company	Stage	Hype Score
Odiparcil	Inventiva	Phase 2	29
laronidase	Sanofi	Approved	43
Laronidase	Sanofi	Approved	43
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)	Sanofi	Phase 2	35
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)	Sanofi	Approved	43
Laronidase + Cyclosporine A (CsA) + Azathioprine (Aza)	Sanofi	Phase 1/2	32
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)	Sanofi	Phase 3	40
rhIDU (recombinant human-Alpha-L-Iduronidase) + Placebo	Sanofi	Phase 3	40
Aldurazyme + Aldurazyme + placebo	Sanofi	Phase 3	40
Laronidase	Sanofi	Approved	35
JR-141	JCR Pharmaceuticals	Phase 2/3	38
JR-441 + JR-441 + JR-441	JCR Pharmaceuticals	Phase 1/2	36
JR-446	JCR Pharmaceuticals	Phase 1/2	39
JR-171	JCR Pharmaceuticals	Phase 1/2	32
JR-141	JCR Pharmaceuticals	Phase 2	39
JR-141 + Idursulfase + JR-141 or Idursulfase	JCR Pharmaceuticals	Phase 3	44
JR-141	JCR Pharmaceuticals	Phase 3	47
JR-171 (lepunafusp alfa)	JCR Pharmaceuticals	Phase 1/2	32
JR-141	JCR Pharmaceuticals	Phase 1/2	32
JR-141	JCR Pharmaceuticals	Phase 2/3	42